Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic Retinopathy
- 20 March 2006
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 142 (1), 155-157.e1
- https://doi.org/10.1016/j.ajo.2006.02.015
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Macular Edema From Central Retinal Vein OcclusionOphthalmic Surgery, Lasers and Imaging Retina, 2005
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 1994
- Effects of Panretinal Photocoagulation on Rubeosis Iridis, Angle Neovascularization, and Neovascular GlaucomaAmerican Journal of Ophthalmology, 1978